130 related articles for article (PubMed ID: 15556626)
21. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
Thelen P; Schweyer S; Hemmerlein B; Wuttke W; Seseke F; Ringert RH
Int J Oncol; 2004 Jan; 24(1):25-31. PubMed ID: 14654937
[TBL] [Abstract][Full Text] [Related]
22. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
Menendez JA; Lupu R
Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
[TBL] [Abstract][Full Text] [Related]
23. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells.
Wang HQ; Altomare DA; Skele KL; Poulikakos PI; Kuhajda FP; Di Cristofano A; Testa JR
Oncogene; 2005 May; 24(22):3574-82. PubMed ID: 15806173
[TBL] [Abstract][Full Text] [Related]
24. The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells.
Myrthue A; Rademacher BL; Pittsenbarger J; Kutyba-Brooks B; Gantner M; Qian DZ; Beer TM
Clin Cancer Res; 2008 Jun; 14(11):3562-70. PubMed ID: 18519790
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE.
Sepulveda VA; Weigel NL; Falzon M
Steroids; 2006 Feb; 71(2):102-15. PubMed ID: 16243370
[TBL] [Abstract][Full Text] [Related]
26. The role of Vitamin D3 metabolism in prostate cancer.
Lou YR; Qiao S; Talonpoika R; Syvälä H; Tuohimaa P
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):317-25. PubMed ID: 15663995
[TBL] [Abstract][Full Text] [Related]
27. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells.
Van de Sande T; De Schrijver E; Heyns W; Verhoeven G; Swinnen JV
Cancer Res; 2002 Feb; 62(3):642-6. PubMed ID: 11830512
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer.
Knowles LM; Smith JW
BMC Genomics; 2007 Jun; 8():168. PubMed ID: 17565694
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells.
Little JL; Wheeler FB; Fels DR; Koumenis C; Kridel SJ
Cancer Res; 2007 Feb; 67(3):1262-9. PubMed ID: 17283163
[TBL] [Abstract][Full Text] [Related]
30. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
31. Inhibiting long-chain fatty acyl CoA synthetase does not increase agonist-induced release of arachidonate metabolites from human endothelial cells.
Weis MT; Brady M; Moore M; Crumley J; Stallone JN
J Vasc Res; 2005; 42(4):275-83. PubMed ID: 15908751
[TBL] [Abstract][Full Text] [Related]
32. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity.
Swami S; Krishnan AV; Peehl DM; Feldman D
Mol Cell Endocrinol; 2005 Sep; 241(1-2):49-61. PubMed ID: 15955619
[TBL] [Abstract][Full Text] [Related]
33. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays.
Krishnan AV; Shinghal R; Raghavachari N; Brooks JD; Peehl DM; Feldman D
Prostate; 2004 May; 59(3):243-51. PubMed ID: 15042599
[TBL] [Abstract][Full Text] [Related]
34. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
35. Effect of side-chain structure on inhibition of yeast fatty-acid synthase by cerulenin analogues.
Morisaki N; Funabashi H; Shimazawa R; Furukawa J; Kawaguchi A; Okuda S; Iwasaki S
Eur J Biochem; 1993 Jan; 211(1-2):111-5. PubMed ID: 8425521
[TBL] [Abstract][Full Text] [Related]
36. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells.
Khanim FL; Gommersall LM; Wood VH; Smith KL; Montalvo L; O'Neill LP; Xu Y; Peehl DM; Stewart PM; Turner BM; Campbell MJ
Oncogene; 2004 Sep; 23(40):6712-25. PubMed ID: 15300237
[TBL] [Abstract][Full Text] [Related]
37. Constitutive expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in a transformed human proximal tubule cell line: evidence for direct regulation of vitamin D metabolism by calcium.
Bland R; Walker EA; Hughes SV; Stewart PM; Hewison M
Endocrinology; 1999 May; 140(5):2027-34. PubMed ID: 10218951
[TBL] [Abstract][Full Text] [Related]
38. Regulation of cholesterol 25-hydroxylase expression by vitamin D3 metabolites in human prostate stromal cells.
Wang JH; Tuohimaa P
Biochem Biophys Res Commun; 2006 Jun; 345(2):720-5. PubMed ID: 16696936
[TBL] [Abstract][Full Text] [Related]
39. Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma.
Moore S; Knudsen B; True LD; Hawley S; Etzioni R; Wade C; Gifford D; Coleman I; Nelson PS
Int J Cancer; 2005 Apr; 114(4):563-71. PubMed ID: 15609334
[TBL] [Abstract][Full Text] [Related]
40. Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway.
Swinnen JV; Heemers H; Deboel L; Foufelle F; Heyns W; Verhoeven G
Oncogene; 2000 Oct; 19(45):5173-81. PubMed ID: 11064454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
